Journal: Oncology Reports

Article Title: JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T-cell lymphoma, nasal type

doi: 10.3892/or.2019.7112

Figure Lengend Snippet: Tofacitinib, a JAK3 inhibitor, affects EN-NK/T-NT cell growth and CC. (A) YT, NKL and NK92 cells were treated with the indicated concentrations of tofacitinib, and viable cells were counted at the indicated time-points, using the trypan blue exclusion test. Growth of YT, NKL, and NK92 cells were significantly inhibited following treatment with tofacitinib at 50 and 100 nM. Values are expressed as the means ± SE of the results from at least 3 independent experiments, each with triplicate measurements (n≥3); *P<0.05 as compared with the DMSO-treated cells. (B) The 3 cell lines were treated with DMSO or 100 nM tofacitinib for 48 h, in order to assess CC profiles using flow cytometry. Following treatment, a significant increase was observed in the percentage of cells at the G1 phase and a concomitant reduction in the percentage of cells at the S and G2 phases in the 3 cell types. Values are presented as the mean ± SE from triplicate experiments (P<0.05 as compared with DMSO-treated cells). EN-NK/T-NT, extranodal NK/T-cell lymphoma, nasal type; SE, standard error; DMSO, dimethyl sulfoxide; CC, cell cycle.

Article Snippet: Cells were seeded at 2×10 5 cells/ml/well in 24-well plates and treated with tofacitinib (50 and 100 nM) (cat. no. 14703; Cell Signaling Technology, Inc., Danvers, MA, USA) and Stattic (1, 2, 5 and 10 μM) (cat. no. HY-13818; MedChemExpress, Inc., Shanghai, China) at indicated concentrations for 24 and 48 h, with dimethyl sulfoxide (DMSO) used as the control, before being subjected to cell counting and MTS assays.

Techniques: Flow Cytometry